Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged

Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.